NEW YORK (GenomeWeb News) – IntelligentMDx said today that it has entered into a development and licensing agreement to design, develop, and manufacture CE-marked and US Food and Drug Administration-cleared diagnostic tests for use on Qiagen's QIAsymphony RGQ platform.
IMDx did not disclose the assays, but said they will be incorporated into Qiagen's growing portfolio of molecular diagnostic assays and be distributed worldwide by Qiagen. Qiagen also retained the rights to manufacture the assays pursuant to volume considerations, IMDx said.
Further financial and other terms of the multi-year deal were not disclosed.
"This collaboration will help us to accelerate the expansion of our test menu for the QIAsymphony RGQ," Dirk Zimmermann, vice president and head of development Molecular Diagnostics Europe and Asia for Qiagen, said in a statement. The deal with IMDx "helps us to maximize the value of QIAsymphony RGQ for our customers by giving them the opportunity to consolidate an expanding range of molecular tests on one system."
Based in Cambridge, Mass., IntelligentMDx develops molecular tests based on a proprietary bioinformatics platform that "allows for efficient design of robust and accurate diagnostics that can be formatted for a variety of real-time PCR platforms," the company said.